<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>James Routley | Feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://www.mpip-mainz.mpg.de/en/press/pr-2022-22">Original</a>
    <h1>Study shows antibodies against PEG in 83% of the German population</h1>
    
    <div id="readability-page-1" class="page"><div>
  
  
  
  <p>Study shows antibodies against polyethylene glycol in 83 percent of the German population</p>
  

  <div>
    <p><span>October 16, 2023</span>
    </p>
    
  </div>

  <p>It has long been known that people can form defenses and thus antibodies against viruses. But antibodies can also develop against polyethylene glycol (PEG), a substance used in cosmetics, food and medicine. These influence the effectiveness of drugs. A team of researchers from the Max Planck Institute for Polymer Research has now investigated how widespread these antibodies already are in German society and how they might influence medical therapies using nanocarriers.</p>
  
  
<figure data-description="Anti-PEG antibodies circulate in the blood of many people and bind to PEGylated nanocarriers" data-picture="base64;<picture class="" data-iesrc="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MTQwMCwiZmlsZV9leHRlbnNpb24iOiJqcGciLCJvYmpfaWQiOjg4MTI5MH0%3D--fd2c64c0a1a9d726b2a6aa4feccb5b57a30f0a58" data-alt="Anti-PEG antibodies circulate in the blood of many people and bind to PEGylated nanocarriers" data-class=""><source media="(max-width: 767px)" srcset="/881290/original-1697367387.webp?t=eyJ3aWR0aCI6NDE0LCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--755904b1a79a7929fa0e2d7542075f13267a1b05 414w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6Mzc1LCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--725c5d73fe12be804c540d12e7454ded6ad52907 375w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6MzIwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--c9aa6963f13e3ad5249c5e82edc62a9ccac2db1f 320w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6NDExLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--fddeae70e7d1ed1d9fead6a90d8c5952d5f73157 411w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6NDgwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--c27cff16d85995f5e14a6507483adbf91e499ab9 480w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6MzYwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--27bd52241ffa3c71dd891b03adbe734fe308bd4d 360w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6ODI4LCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--556e8cc2c2f1ffce0f8ff59b36c73c569dde13df 828w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6NzUwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--78f91df178c48c9a8c89ef81a17ea0686ab7a76e 750w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6NjQwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--ce3d9fee4b9dec8408e89a17584935f5df5afee4 640w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6ODIyLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--52e1a046d74f1a5dfd599750a2f764ed042df294 822w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6OTYwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--b1164ae98eef88fda7e693f00e3b6010a71579f3 960w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6NzIwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--3cc2800ed006bfbffbf15a837d00ec44d9f28f98 720w" sizes="100vw" type="image/webp" /><source media="(max-width: 767px)" srcset="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NDE0LCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--af0ad004477459e0ea8ae53ce63e5439bd9e68fe 414w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6Mzc1LCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--d0378e94910bb029b137288daa61697b1bf41cc9 375w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MzIwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--6be3a09c3c60c67b852933237098c4e06ec38014 320w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NDExLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--e1cfd5aeb1f9c216af4f6d90c379d0f61edbc151 411w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NDgwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--28430e7eb9b04905e7f32e824894258a7cd733c3 480w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MzYwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--ffae65b452d08711fa72ea7a95e19789a07eeaec 360w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6ODI4LCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--32f63d7b931f3e3f904eb0bf335d5443f91666a9 828w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NzUwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--a06367c925c699c502ceef8f7225901536bb96f7 750w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NjQwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--359f6b33ede851f8544e436a9871a34d1c6cb504 640w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6ODIyLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--5fa7305f1891f9466a3de6c9ef5d01dc627a5be0 822w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6OTYwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--03c0815571eed715cb22d9ef0dee1035480ac0fd 960w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NzIwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--e8ef54d975ffb5ee8b9347b27647d6850adab762 720w" sizes="100vw" type="image/jpeg" /><source media="(min-width: 768px) and (max-width: 991px)" srcset="/881290/original-1697367387.webp?t=eyJ3aWR0aCI6OTAwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--349cd8aa5044af88b106cc824b3528b512699318 900w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6MTgwMCwiZmlsZV9leHRlbnNpb24iOiJ3ZWJwIiwib2JqX2lkIjo4ODEyOTB9--c5814f1464aca72008161a245799f56da4020bd4 1800w" sizes="900px" type="image/webp" /><source media="(min-width: 768px) and (max-width: 991px)" srcset="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6OTAwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--557503f8a9313f5f222ae84fe91a41e1facf60c1 900w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MTgwMCwiZmlsZV9leHRlbnNpb24iOiJqcGciLCJvYmpfaWQiOjg4MTI5MH0%3D--894ce05c7d78bf20347dbc4bda9905a421b4b978 1800w" sizes="900px" type="image/jpeg" /><source media="(min-width: 992px) and (max-width: 1199px)" srcset="/881290/original-1697367387.webp?t=eyJ3aWR0aCI6MTIwMCwiZmlsZV9leHRlbnNpb24iOiJ3ZWJwIiwicXVhbGl0eSI6ODYsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--7c1f4798696bc8e7033a7de35dd267474f7f230f 1200w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6MjQwMCwiZmlsZV9leHRlbnNpb24iOiJ3ZWJwIiwib2JqX2lkIjo4ODEyOTB9--9821a7546e5a76dfb26a3fea9f130617347f938c 2400w" sizes="1200px" type="image/webp" /><source media="(min-width: 992px) and (max-width: 1199px)" srcset="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MTIwMCwiZmlsZV9leHRlbnNpb24iOiJqcGciLCJvYmpfaWQiOjg4MTI5MH0%3D--8881ee14613f917948ae890dff7ceea1ef2f76bb 1200w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MjQwMCwiZmlsZV9leHRlbnNpb24iOiJqcGciLCJvYmpfaWQiOjg4MTI5MH0%3D--e6f96412f0532e962edf25709f688f3647e8f60d 2400w" sizes="1200px" type="image/jpeg" /><source media="(min-width: 1200px)" srcset="/881290/original-1697367387.webp?t=eyJ3aWR0aCI6MTQwMCwiZmlsZV9leHRlbnNpb24iOiJ3ZWJwIiwicXVhbGl0eSI6ODYsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--115e29325f668828ab223629577ace3fd3231711 1400w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6MjgwMCwiZmlsZV9leHRlbnNpb24iOiJ3ZWJwIiwib2JqX2lkIjo4ODEyOTB9--fe6002eb7771f9f3574fe82969ce28fb08339e95 2800w" sizes="1400px" type="image/webp" /><source media="(min-width: 1200px)" srcset="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MTQwMCwiZmlsZV9leHRlbnNpb24iOiJqcGciLCJvYmpfaWQiOjg4MTI5MH0%3D--fd2c64c0a1a9d726b2a6aa4feccb5b57a30f0a58 1400w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MjgwMCwiZmlsZV9leHRlbnNpb24iOiJqcGciLCJvYmpfaWQiOjg4MTI5MH0%3D--27b15c040ab251f8298cd032980e674bebde424e 2800w" sizes="1400px" type="image/jpeg" /><img alt="Anti-PEG antibodies circulate in the blood of many people and bind to PEGylated nanocarriers" class="" title="Anti-PEG antibodies circulate in the blood of many people and bind to PEGylated nanocarriers" src="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MTQwMCwiZmlsZV9leHRlbnNpb24iOiJqcGciLCJvYmpfaWQiOjg4MTI5MH0%3D--fd2c64c0a1a9d726b2a6aa4feccb5b57a30f0a58" /></picture>">
      <div data-href="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6ODAwLCJoZWlnaHQiOjYwMCwib2JqX2lkIjo4ODEyOTB9--13ea4afecd8e8367125246589e0199be21b7418c " title="opens zoom view">
      <div>
        <picture data-iesrc="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6ODQ4LCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--0d96416dedf3706cf286f7bbd636433329106fc7" data-alt="Anti-PEG antibodies circulate in the blood of many people and bind to PEGylated nanocarriers" data-class="img-responsive"><source media="(max-width: 767px)" srcset="data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A//www.w3.org/2000/svg%22%20width%3D%221%22%20height%3D%221%22%3E%3C/svg%3E 1w" sizes="100vw" type="image/webp" data-srcset="/881290/original-1697367387.webp?t=eyJ3aWR0aCI6NDE0LCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--755904b1a79a7929fa0e2d7542075f13267a1b05 414w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6Mzc1LCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--725c5d73fe12be804c540d12e7454ded6ad52907 375w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6MzIwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--c9aa6963f13e3ad5249c5e82edc62a9ccac2db1f 320w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6NDExLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--fddeae70e7d1ed1d9fead6a90d8c5952d5f73157 411w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6NDgwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--c27cff16d85995f5e14a6507483adbf91e499ab9 480w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6MzYwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--27bd52241ffa3c71dd891b03adbe734fe308bd4d 360w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6ODI4LCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--556e8cc2c2f1ffce0f8ff59b36c73c569dde13df 828w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6NzUwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--78f91df178c48c9a8c89ef81a17ea0686ab7a76e 750w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6NjQwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--ce3d9fee4b9dec8408e89a17584935f5df5afee4 640w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6ODIyLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--52e1a046d74f1a5dfd599750a2f764ed042df294 822w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6OTYwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--b1164ae98eef88fda7e693f00e3b6010a71579f3 960w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6NzIwLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--3cc2800ed006bfbffbf15a837d00ec44d9f28f98 720w"/><source media="(max-width: 767px)" srcset="data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A//www.w3.org/2000/svg%22%20width%3D%221%22%20height%3D%221%22%3E%3C/svg%3E 1w" sizes="100vw" type="image/jpeg" data-srcset="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NDE0LCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--af0ad004477459e0ea8ae53ce63e5439bd9e68fe 414w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6Mzc1LCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--d0378e94910bb029b137288daa61697b1bf41cc9 375w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MzIwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--6be3a09c3c60c67b852933237098c4e06ec38014 320w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NDExLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--e1cfd5aeb1f9c216af4f6d90c379d0f61edbc151 411w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NDgwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--28430e7eb9b04905e7f32e824894258a7cd733c3 480w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MzYwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--ffae65b452d08711fa72ea7a95e19789a07eeaec 360w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6ODI4LCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--32f63d7b931f3e3f904eb0bf335d5443f91666a9 828w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NzUwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--a06367c925c699c502ceef8f7225901536bb96f7 750w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NjQwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--359f6b33ede851f8544e436a9871a34d1c6cb504 640w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6ODIyLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--5fa7305f1891f9466a3de6c9ef5d01dc627a5be0 822w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6OTYwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--03c0815571eed715cb22d9ef0dee1035480ac0fd 960w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NzIwLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--e8ef54d975ffb5ee8b9347b27647d6850adab762 720w"/><source media="(min-width: 768px) and (max-width: 991px)" srcset="data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A//www.w3.org/2000/svg%22%20width%3D%221%22%20height%3D%221%22%3E%3C/svg%3E 1w" sizes="751px" type="image/webp" data-srcset="/881290/original-1697367387.webp?t=eyJ3aWR0aCI6NzUxLCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJvYmpfaWQiOjg4MTI5MH0%3D--4588eed40f4b43a9fe94dde2dbfc0e14e9bb3c19 751w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6MTUwMiwiZmlsZV9leHRlbnNpb24iOiJ3ZWJwIiwib2JqX2lkIjo4ODEyOTB9--fac9b564747aa6a4d65cc1021561dd715b7ebfc8 1502w"/><source media="(min-width: 768px) and (max-width: 991px)" srcset="data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A//www.w3.org/2000/svg%22%20width%3D%221%22%20height%3D%221%22%3E%3C/svg%3E 1w" sizes="751px" type="image/jpeg" data-srcset="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6NzUxLCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--84524c00c85497dc041fea664ca80f687ec3de27 751w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MTUwMiwiZmlsZV9leHRlbnNpb24iOiJqcGciLCJvYmpfaWQiOjg4MTI5MH0%3D--9b617da150e12bd34a845d2b3c5e4d756222f294 1502w"/><source media="(min-width: 992px) and (max-width: 1199px)" srcset="data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A//www.w3.org/2000/svg%22%20width%3D%221%22%20height%3D%221%22%3E%3C/svg%3E 1w" sizes="698px" type="image/webp" data-srcset="/881290/original-1697367387.webp?t=eyJ3aWR0aCI6Njk4LCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJxdWFsaXR5Ijo4Niwib2JqX2lkIjo4ODEyOTB9--2c08a05195d3b5e8724c0a2baaafadb98e0b0a88 698w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6MTM5NiwiZmlsZV9leHRlbnNpb24iOiJ3ZWJwIiwib2JqX2lkIjo4ODEyOTB9--c6e7d873c6b0215e228c0895f4f32b443b2ebb05 1396w"/><source media="(min-width: 992px) and (max-width: 1199px)" srcset="data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A//www.w3.org/2000/svg%22%20width%3D%221%22%20height%3D%221%22%3E%3C/svg%3E 1w" sizes="698px" type="image/jpeg" data-srcset="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6Njk4LCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--ae46905fec750373b87201d81938b513ab44c131 698w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MTM5NiwiZmlsZV9leHRlbnNpb24iOiJqcGciLCJvYmpfaWQiOjg4MTI5MH0%3D--0e57ebdb9b6433968939b60dc90de8a546c2e876 1396w"/><source media="(min-width: 1200px)" srcset="data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A//www.w3.org/2000/svg%22%20width%3D%221%22%20height%3D%221%22%3E%3C/svg%3E 1w" sizes="848px" type="image/webp" data-srcset="/881290/original-1697367387.webp?t=eyJ3aWR0aCI6ODQ4LCJmaWxlX2V4dGVuc2lvbiI6IndlYnAiLCJxdWFsaXR5Ijo4Niwib2JqX2lkIjo4ODEyOTB9--57d388ced44eca5d7cb93aa0d9dc201fee4db106 848w, /881290/original-1697367387.webp?t=eyJ3aWR0aCI6MTY5NiwiZmlsZV9leHRlbnNpb24iOiJ3ZWJwIiwib2JqX2lkIjo4ODEyOTB9--ae6b144454cf6169f9d44932c086731c66c37fb7 1696w"/><source media="(min-width: 1200px)" srcset="data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A//www.w3.org/2000/svg%22%20width%3D%221%22%20height%3D%221%22%3E%3C/svg%3E 1w" sizes="848px" type="image/jpeg" data-srcset="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6ODQ4LCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--0d96416dedf3706cf286f7bbd636433329106fc7 848w, /881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MTY5NiwiZmlsZV9leHRlbnNpb24iOiJqcGciLCJvYmpfaWQiOjg4MTI5MH0%3D--4109951b3e2fa19650379ab2ca89d47b79722be4 1696w"/><img alt="Anti-PEG antibodies circulate in the blood of many people and bind to PEGylated nanocarriers" data-src="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6ODQ4LCJmaWxlX2V4dGVuc2lvbiI6ImpwZyIsIm9ial9pZCI6ODgxMjkwfQ%3D%3D--0d96416dedf3706cf286f7bbd636433329106fc7" title="Anti-PEG antibodies circulate in the blood of many people and bind to PEGylated nanocarriers" src="data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A//www.w3.org/2000/svg%22%20width%3D%221%22%20height%3D%221%22%3E%3C/svg%3E"/></picture>
        
      </div>
    </div>
      <img src="data:image/svg+xml,%3Csvg%20xmlns%3D%22http%3A//www.w3.org/2000/svg%22%20width%3D%221%22%20height%3D%221%22%3E%3C/svg%3E" alt="Anti-PEG antibodies circulate in the blood of many people and bind to PEGylated nanocarriers" data-src="/881290/original-1697367387.jpg?t=eyJ3aWR0aCI6MjQ2LCJvYmpfaWQiOjg4MTI5MH0%3D--c29de5f4de6a5d6259e28b3f3f5e583343cc93d6"/>

    <figcaption>
        <p>Anti-PEG antibodies circulate in the blood of many people and bind to PEGylated nanocarriers</p>
        <p>
          Anti-PEG antibodies circulate in the blood of many people and bind to PEGylated nanocarriers
        </p>
    </figcaption>
</figure>

<p>A virus invades the body and the immune system begins to work: Antibodies develop that fight the infection. At the same time, an immune memory builds up so that antibodies can be quickly made available in the event of a new infection. Surprisingly, antibodies can also form against polyethylene glycol (PEG), a molecule with a fairly simple structure.</p><p>In addition to cosmetic products - from creams, perfumes and lotions to lipstick - polyethylene glycol is also used in medicine. Here, it serves as a kind of camouflage coat against the body&#39;s own immune system, thus increasing the circulation time of an active ingredient in the blood.</p><p>&#34;For us, PEG is interesting for coating nano-sized drug carriers with it,&#34; says Svenja Morsbach, group leader in Katharina Landfester&#39;s department at the MPI for Polymer Research. In this way, the researchers achieve a longer circulation time for the drug capsules, which are only nanometers in size and could be an important component in novel cancer therapies in the future, for example.</p><p>In their studies, the team led by Morsbach and Landfester examined more than 500 blood samples from patients taken in 2019. &#34;The antibodies formed against PEG attach themselves to the coated nanocarriers, thus counteracting the effect that is actually desired: the nanocarrier becomes visible to the immune system and is removed before it can exert its effect,&#34; explains Katharina Landfester, director of the department.</p><p>The researchers led by Morsbach and Landfester assume that therapies will have to be adapted in the future to respond to this behavior of the immune system. In their statistical studies of blood samples, they found that PEG antibodies were already detectable in 83% of the samples examined.</p><p>The concentration of PEG antibodies in the blood correlates antiproportionally with the age of the person examined: the older the person, the fewer PEG antibodies were present. &#34;We currently assume that this is due to the increasing use of PEG in various areas of life only recently and the variation of the immune system in age,&#34; says Morsbach.</p><p>In further studies, the researchers would now like to find out how future therapies could be adapted to compensate for the reduced camouflage of the nanocarriers. &#34;Ideas would include whether PEG can be replaced or possibly dispensed with altogether,&#34; Morsbach said. But determining the antibody concentration in a patient&#39;s blood and individually adjusting the amount of active ingredient could also be an alternative.</p><p>They have published their current results in the renowned journal &#34;Nanoscale Horizons&#34;.</p>
  
</div></div>
  </body>
</html>
